U.S. Markets open in 7 hrs 25 mins
  • S&P Futures

    3,757.25
    -32.25 (-0.85%)
     
  • Dow Futures

    30,530.00
    -251.00 (-0.82%)
     
  • Nasdaq Futures

    11,421.00
    -108.50 (-0.94%)
     
  • Russell 2000 Futures

    1,687.20
    -20.80 (-1.22%)
     
  • Crude Oil

    104.68
    -1.08 (-1.02%)
     
  • Gold

    1,798.00
    -9.30 (-0.51%)
     
  • Silver

    20.11
    -0.17 (-0.82%)
     
  • EUR/USD

    1.0470
    -0.0013 (-0.1256%)
     
  • 10-Yr Bond

    2.9720
    0.0000 (0.00%)
     
  • Vix

    28.71
    +0.55 (+1.95%)
     
  • GBP/USD

    1.2135
    -0.0040 (-0.3289%)
     
  • USD/JPY

    134.7870
    -0.9410 (-0.6933%)
     
  • BTC-USD

    19,490.19
    -507.91 (-2.54%)
     
  • CMC Crypto 200

    418.35
    -13.12 (-3.04%)
     
  • FTSE 100

    7,169.28
    -143.04 (-1.96%)
     
  • Nikkei 225

    25,951.28
    -441.76 (-1.67%)
     

Gracell Biotechnologies to Participate in B Riley Securities 2022 Virtual Oncology Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SUZHOU, China and PALO ALTO, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the B Riley Securities 2022 Virtual Oncology Conference from January 27th to 28th.

The Gracell team is scheduled to have a presentation at 2:30pm - 3:30pm Eastern Time, January 27th and will host virtual investor meetings at the conference on January 27th and 28th.

A webcast of the presentation will be available on the "Events and Presentations" page of the Investors section of the Company's website. A replay of the webcast will be available for 90 days following the event. For more information, please visit ir.gracellbio.com.

About Gracell
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR, TruUCAR and SMART CARTTM technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.

Media contact
Marvin Tang
marvin.tang@gracellbio.com

Investor contact
Gracie Tong
gracie.tong@gracellbio.com